ReportsWeb- Global Non-Alcoholic Steatohepatitis NASH Drugs Ma

Global Non-Alcoholic Steatohepatitis NASH Drugs Market: Industry
Analysis & Outlook 2016-2025
ReportsWeb.com published “Non-Alcoholic Steatohepatitis NASH Drugs Market” from its
database. The report covers the market landscape and its growth prospects over the coming
years. The report also includes a discussion of the key vendors operating in this market.
Non-alcoholic steatohepatitis or NASH is a common term for "silent" liver disease. It resembles
alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in
NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well
and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can
lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to
work properly.
There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-
alcoholic fatty liver disease (NAFLD) . NASH is also associated with lysosomal acid lipase
deficiency. Patients with only steatosis but no fibrosis can progress to NASH. NASH itself can
remain asymptomatic for years, or it can progress to cirrhosis and hepatocellular carcinoma.
Risk factors such as insulin resistance related to obesity are central to the pathogenesis of
NASH. Methods to diagnose NASH include MRI, CT or X-rays, however, only liver biopsy is
reliable. There are no approved NASH drugs available in the market, but they are expected to
enter the market by 2020. The potential NASH drug candidate include Elafirbranor, OCA, CVC
and Aramchol. Currently, off-label drugs and therapies are employed to counter the
progression of NASH.
For more information about this report: http://www.reportsweb.com/global-non-alcoholic-
steatohepatitis-nash-drugs-market-industry-analysis-and-outlook-2016-2025
The global NASH drugs market is expected to experience robust growth post the launch of
NASH therapeutic drugs, primarily due to increasing patient base, rise in obese population,
increasing number of people suffering from type-2 diabetes coupled with increasing healthcare
expenditure. However, the market growth is hindered by the unavailability of effective
biomarkers, high cost of drugs and undefined pathogenesis.
The report "Global NASH Drugs Market: Industry Analysis & Outlook (2016-2020) " analyzes the
development of this market, with focus on the US and Europe markets. The major trends,
growth drivers as well as issues being faced by the market are discussed in detail in this report.
The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Tobira Therapeutics Inc. and